Verasolve
Confidential · June 2026

94% of CNS drugs fail. On the measurement, not the molecule.

Every subjective endpoint in neurology and psychiatry carries a 30–50% placebo response that drowns the real drug effect. Pharma spends $32B a year on CNS trials, and most of the failures trace to the readout, not the chemistry. That makes it a software problem, and software is what we build.

µLang · Intent Compiler NIRVANA · Inference Engine Clinical Framework · Evidence FDA-aligned provenance
The problem

The endpoints can't tell a working drug from a placebo.

% syllables stuttered, HAM-D, CAPS-5: these scores move whether or not the drug is working. A 30–50% placebo response swamps the signal, so good molecules get killed at the readout. Change the instrument and you change which drugs survive.

The platform

This started as research, not a product hunt. Three lines of work kept landing on the same idea: you can compile what you do and don't know into rules a machine enforces. Three parts, one pipeline.

01

µLang

The Intent Compiler

Turns scientific knowledge into rules the system has to follow. Every number traces back to a source, and the build breaks if a claim isn't backed. FORBID and ENSURE rules stop the model claiming more than the data supports.

309 tests · 3 Rust crates · v5.1
02

NIRVANA

The Inference Engine

The engine that runs those rules as text is generated. A FORBID rule isn't a prompt the model can talk its way around; it's a hard limit on what it's allowed to say. In clinical use, that's the line between a helpful guess and an answer you can stand behind.

Safety rules enforced at the output, not prompted
03

Clinical Framework

The Evidence Layer

Already running and validated on two diseases, stuttering and amyloidosis. A six-channel composite endpoint cut the placebo response from 35% to 15.4% and raised the measurable effect size by 1.3–1.4×, enough to move a trial from inconclusive to a clear read.

AUC 0.742 · SEP-28k n=18,039 · Aβ42 MD
How the pipeline runs
1Encode

Experts write what's known, and what isn't, as µLang contracts with sources attached.

2Compile

µLang turns those contracts into hard constraints with confidence bounds.

3Generate

NIRVANA produces results that can't break the constraints.

4Test

The Clinical Framework checks every output against real data and tries to break it.

↺  When a test catches the system overclaiming, that failure becomes a new constraint. Failure is data. Cross-attention got falsified; the Leu17 overprediction was caught before it shipped.
Why now

The FDA's recent guidance on real-world evidence and AI in drug development asks for the things µLang already does: every computational claim traceable to a source, stated with its confidence, with safety limits that actually hold.

We've been building to that bar. The rules are catching up to us.

Validation & moat

The moat is the compiler: hard to rebuild, weeks to aim at a new disease.

94%
of CNS drugs fail in Phase 2. That's the problem we take out.
0.742
Prolongation AUC, speaker-independent, on SEP-28k (n=18,039)
56%
less placebo response with our composite endpoint (35% to 15.4%)
8–14wk
to stand up a new disease on the existing compiler.
541 µLang contracts · 266 FORBID rules
Two diseases validated end to end: stuttering & amyloidosis
Aβ42 MD: Leu17 flagged as the top aggregation anchor (novel, testable)
Every claim tagged with its evidence level
Figures from internal validation. Each claim is tagged verified, architectural, or derived. Confidential.
The people building it
Dr. Tanbir Dhingra
Chief Executive Officer
Physician-operator
Jake Martin
Chief Technology Officer
µLang · NIRVANA
Jeff Davis
Chief Marketing Officer
Walmart · Intuit
Jens Heitmann
Chief Operating Officer
AI-native ops
Moses Herrera
Chief Revenue Officer
Med / health sales
Jeff Barlow
Chief Financial Officer
Finance & Ops
Leadership in depth

Dr. Tanbir Dhingra

Chief Executive Officer

Physician-trained operator who runs every business on a single principle: diagnose before you prescribe. He doesn't advise, he operates, with personal capital on the line, equity at stake, and full accountability for the outcome. Under AGG he took a pre-owned auto dealership from $250K to $1.4M per month (797th to #1 in Canada on Dealertrack in under 90 days), scaled TrustSimpli from zero to $1M in monthly revenue in 120 days, grew a BC franchise brand from 10 to 20+ locations in a year, and built Upsist, a global VA operation serving 300+ clients across 7 countries, all from personal capital with no outside investors or loans.

AGG founderDealership #1 in CanadaTrustSimpli 0→$1M/moUpsist · 300+ clientsPhysician-trained

Jake Martin

Chief Technology Officer

The scientific and technical core of Verasolve, and author of the µLang compiler (v5.1), the NIRVANA inference architecture, and the stuttering and amyloidosis clinical research that proves the platform end to end. A principal systems architect and CISO for compliance-critical systems: security-by-design and zero-trust for regulated environments (HIPAA, SOC 2, audit readiness), Rust and Cloudflare-native, and creator of HealthFees, a healthcare price-transparency engine.

µLangNIRVANAHIPAA / SOC 2RustHealthFees

Jeff Davis

Chief Marketing Officer

Two decades building and scaling ventures across FinTech, HealthTech and MarTech. Leads a multi-layered product and growth organization at Walmart and built an agentic AI capability that sharply reduced manual marketing work. Owned a nine-figure performance-marketing P&L across Williams-Sonoma's brands and scaled QuickBooks organic growth into 12+ countries at Intuit. He's how hard technology reaches the market.

WalmartIntuitWilliams-Sonoma9-figure P&LGTM

Jens Heitmann

Chief Operating Officer

An AI-native operator who designs and runs the systems companies depend on, with one method behind all of it: diagnose the bottleneck, design the system, implement it. He doesn't hand over a strategy and walk away; he wires the AI into the operation and runs it, and consults worldwide on AI implementation and execution. With a supporting background in cybersecurity for the security-critical side of a regulated platform, his work has generated over $8M for clients across multiple industries, grown AI for Business from $0 to $3M ARR in seven months, and taken PrimeStar Solutions in Colorado from $0 to $4M in nine months: the same play, company after company.

COOGlobal AI implementationAI for Business 0→$3M ARR$8M+ generated

Moses Herrera

Chief Revenue Officer

Revenue leader whose edge is sales psychology and sales engineering: turning complex, technical products into clear buying decisions. He's sold across several industries, including medical and health, so he already knows how care organizations evaluate and buy.

Sales psychologySales engineeringMedical & health salesMulti-industry

Jeff Barlow

Chief Financial Officer

Entrepreneur and executive with deep experience across construction, energy, finance and operations, having founded, scaled and led multiple companies in CFO and COO roles. His background spans financial management, accounting and banking relationships, payroll, project execution and operational teams. He specializes in building scalable systems, improving operational efficiency, and forging strategic partnerships that drive sustainable, long-term value.

CFOFinance & OpsMulti-industryScaling systems
Verasolve

The measurement layer for the next decade of CNS medicine.